• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

    6/12/24 7:32:56 PM ET
    $KRON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KRON alert in real time by email
    SC 13D/A 1 ef20031088_formsc13da.htm SC 13D/A


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

    KRONOS BIO, INC.
    (Name of Issuer)

    Common Stock
    (Title of Class of Securities)

    50107A104
    (CUSIP Number)

    Norbert Bischofberger, Ph.D.
    1300 So. El Camino Real, Suite 400
    San Mateo, California 94402
    Telephone: (650) 781-5200
     (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

    June 10, 2024
    (Date of Event Which Requires Filing of This Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


    CUSIP No. 50107A104

    1.
    Name of Reporting Persons. I.R.S. Identification No(s). of above person(s) (entities only)
     
    Norbert Bischofberger, Ph.D.
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC USE ONLY
    4.
    Source of Funds (See Instructions)
    PF
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    Not applicable
    6.
    Citizenship or Place of Organization
     
    Norbert Bischofberger, Ph.D.:  USA
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    7.
    Sole Voting Power
    5,721,326 (1)
    8.
    Shared Voting Power
    8,430,616 Shares (2)
    9.
    Sole Dispositive Power
    5,721,326 (1)
    10.
    Shared Dispositive Power
    8,430,616 Shares (2)
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    14,151,942 Shares
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    13.
    Percent of Class Represented by Amount in Row (11)
    23.6% (3)
    14.
    Type of Reporting Person (See Instructions)
    IN

    (1)   Includes 3,378,785 shares of common stock issuable within 60 days of the date of this report upon the vesting and settlement of restricted stock units and the exercise of stock options held by the Reporting Person.
     
    (2)   Includes (a) 7,375,616 shares of common stock beneficially owned by the Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994, of which Dr. Bischofberger is a trustee, (b) 263,750 shares of common stock beneficially owned by Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020, of which Dr. Bischofberger is a trustee, (c) 263,750 shares of common stock beneficially owned by Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020, of which Dr. Bischofberger is a trustee, (d) 263,750 shares of common stock beneficially owned by Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020, of which Dr. Bischofberger is a trustee and (e) 263,750 shares of common stock beneficially owned by Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020, of which Dr. Bischofberger is a trustee.
     
    (3)   This percentage is calculated based on 60,094,409 shares of common stock outstanding as of May 3, 2024 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 9, 2024, plus 3,378,785 shares of common stock underlying the restricted stock units and options described in note (1) above in accordance with Rule 13d-3(d)(1) under the Exchange Act.
     

    CUSIP No. 50107A104

    1.
    Name of Reporting Persons. I.R.S. Identification No(s). of above person(s) (entities only)
     
    Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC USE ONLY
    4.
    Source of Funds (See Instructions)
    PF
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    Not applicable
    6.
    Citizenship or Place of Organization
    California
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    7.
    Sole Voting Power
    7,375,616 Shares
    8.
    Shared Voting Power
    0
    9.
    Sole Dispositive Power
    7,375,616 Shares
    10.
    Shared Dispositive Power
    0
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    7,375,616 Shares
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    13.
    Percent of Class Represented by Amount in Row (11)
    12.3% (1)
    14.
    Type of Reporting Person (See Instructions)
    OO

    (1)   This percentage is calculated based on 60,094,409 shares of common stock outstanding as of May 3, 2024 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 9, 2024.
     

    CUSIP No. 50107A104

    1.
    Name of Reporting Persons. I.R.S. Identification No(s). of above person(s) (entities only)
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC USE ONLY
    4.
    Source of Funds (See Instructions)
    PF
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    Not applicable
    6.
    Citizenship or Place of Organization
    California
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    7.
    Sole Voting Power
    263,750 Shares
    8.
    Shared Voting Power
    0
    9.
    Sole Dispositive Power
    263,750 Shares
    10.
    Shared Dispositive Power
    0
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    263,750 Shares
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    13.
    Percent of Class Represented by Amount in Row (11)
    0.4% (1)
    14.
    Type of Reporting Person (See Instructions)
    OO

    (1)   This percentage is calculated based on 60,094,409 shares of common stock outstanding as of May 3, 2024 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 9, 2024.
     

    CUSIP No. 50107A104

    1.
    Name of Reporting Persons. I.R.S. Identification No(s). of above person(s) (entities only)
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC USE ONLY
    4.
    Source of Funds (See Instructions)
    PF
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    Not applicable
    6.
    Citizenship or Place of Organization
    California
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    7.
    Sole Voting Power
    263,750 Shares
    8.
    Shared Voting Power
    0
    9.
    Sole Dispositive Power
    263,750 Shares
    10.
    Shared Dispositive Power
    0
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    263,750 Shares
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    13.
    Percent of Class Represented by Amount in Row (11)
    0.4% (1)
    14.
    Type of Reporting Person (See Instructions)
    OO

    (1)   This percentage is calculated based on 60,094,409 shares of common stock outstanding as of May 3, 2024 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 9, 2024.
     

    CUSIP No. 50107A104

    1.
    Name of Reporting Persons. I.R.S. Identification No(s). of above person(s) (entities only)
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC USE ONLY
    4.
    Source of Funds (See Instructions)
    PF
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    Not applicable
    6.
    Citizenship or Place of Organization
    California
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    7.
    Sole Voting Power
    263,750 Shares
    8.
    Shared Voting Power
    0
    9.
    Sole Dispositive Power
    263,750 Shares
    10.
    Shared Dispositive Power
    0
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    263,750 Shares
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    13.
    Percent of Class Represented by Amount in Row (11)
    0.4% (1)
    14.
    Type of Reporting Person (See Instructions)
    OO

    (1)   This percentage is calculated based on 60,094,409 shares of common stock outstanding as of May 3, 2024 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 9, 2024.
     

    CUSIP No. 50107A104

    1.
    Name of Reporting Persons. I.R.S. Identification No(s). of above person(s) (entities only)
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020
    2.
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a) ☒
    (b) ☐
    3.
    SEC USE ONLY
    4.
    Source of Funds (See Instructions)
    PF
    5.
    Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)
    Not applicable
    6.
    Citizenship or Place of Organization
    California
    Number of
    Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With:
    7.
    Sole Voting Power
    263,750 Shares
    8.
    Shared Voting Power
    0
    9.
    Sole Dispositive Power
    263,750 Shares
    10.
    Shared Dispositive Power
    0
    11.
    Aggregate Amount Beneficially Owned by Each Reporting Person
    263,750 Shares
    12.
    Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)
    13.
    Percent of Class Represented by Amount in Row (11)
    0.4% (1)
    14.
    Type of Reporting Person (See Instructions)
    OO

    (1)   This percentage is calculated based on 60,094,409 shares of common stock outstanding as of May 3, 2024 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 9, 2024.


    Explanatory Note: This Amendment No. 1, which amends the Schedule 13D filed with the Securities and Exchange Commission (the “SEC”) on November 27, 2023 (the “Original Schedule 13D”) filed on behalf of Norbert Bischofberger, Ph.D., Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994, Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020, Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020, Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020, Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020, (collectively, the “Reporting Persons”) relates to the common stock, $0.001 par value per share (the “Common Stock”), of Kronos Bio, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used but not defined herein have the meanings given to such terms in the Original Schedule 13D.

    Item 3.
    Source and Amount of Funds or Other Consideration

    Item 3 of the Original Schedule 13D is hereby amended and supplemented by adding the following paragraph at the end of Item 3:

    Between June 10, 2024 and June 12, 2024, Norbert Bischofberger, Ph.D., Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994 purchased an aggregate of 3,005,122 shares of Common Stock of the Issuer in the open market at purchase prices ranging from $0.7392 to $1.30 per share.

    Item 5.
    Interest in Securities of the Issuer

    Item 5 of the Original Schedule 13D is hereby amended and restated in its entirety as follows:

    (a) (b) The following information with respect to the ownership of Common Stock of the Issuer by the persons filing this statement on Schedule 13D is provided as of June 12, 2024:

    Reporting Person
     
    Shares Held
    Directly
       
    Sole
    Voting
    Power
       
    Shared
    Voting
    Power
       
    Sole
    Dispositive
    Power
       
    Shared
    Dispositive
    Power
       
    Beneficial
    Ownership
       
    Percentage
    of Class(2)
     
    Norbert Bischofberger, Ph.D. (1)
       
    5,721,326
         
    5,721,326
         
    8,430,616
         
    5,721,326
         
    8,430,616
         
    14,151,942
         
    23.6
    %
                                                             
    Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994
       
    7,375,616
         
    7,375,616
         
    0
         
    7,375,616
         
    0
         
    7,375,616
         
    12.3
    %
                                                             
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020
       
    263,750
         
    263,750
         
    0
         
    263,750
         
    0
         
    263,750
         
    0.4
    %
                                                             
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020
       
    263,750
         
    263,750
         
    0
         
    263,750
         
    0
         
    263,750
         
    0.4
    %
     


    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020
       
    263,750
         
    263,750
         
    0
         
    263,750
         
    0
         
    263,750
         
    0.4
    %
                                                             
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020
       
    263,750
         
    263,750
         
    0
         
    263,750
         
    0
         
    263,750
         
    0.4
    %

    (1)           Includes an aggregate of 3,378,785 shares of common stock underlying restricted stock units and options which have vested or will vest within sixty (60) days of this Schedule 13D.

    (2)           This percentage is calculated based on (i) 60,094,409 shares of common stock outstanding as of May 3, 2024 as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 9, 2024 and (ii) 3,378,785 shares of common stock underlying the restricted stock units and options, as applicable.

    (c) Except as set forth herein, the Reporting Person has not effected any transactions in shares of the Issuer’s Common Stock during the last 60 days.

    (d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the shares of Common Stock beneficially owned by the Reporting Person.

    (e) Not applicable.

    Item 7. Material to be Filed as Exhibits.

    A.
    Agreement regarding filing of joint Schedule 13D.
     

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: June 12, 2024

     
    /s/ Norbert Bischofberger, Ph.D.
     
    Norbert Bischofberger, Ph.D.
         
     
    Norbert W. & Inger A. Bischofberger Revocable Inter Vivos Trust, dtd August 29, 1994
         
     
    By:
    /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee
         
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Exempt Trust dated April 29, 2020
         
     
    By:
    /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee
         
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the David Michael Anthony Dynasty GST Non-Exempt Trust dated April 29, 2020
         
     
    By:
    /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee
         
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Exempt Trust dated April 29, 2020
         
     
    By:
    /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee
         
     
    Norbert W. Bischofberger and Inger A. Bischofberger, Trustees of the Irene Alisha Bischofberger Dynasty GST Non-Exempt Trust dated April 29, 2020
         
     
    By:
    /s/ Norbert Bischofberger, Ph.D.
     
    Name:
    Norbert Bischofberger, Ph.D., Trustee



    Get the next $KRON alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $KRON

    DatePrice TargetRatingAnalyst
    11/14/2024$6.00 → $1.00Overweight → Neutral
    Piper Sandler
    11/14/2024Buy → Hold
    TD Cowen
    9/14/2022$12.00Buy
    Berenberg
    2/28/2022$50.00 → $30.00Overweight
    Piper Sandler
    11/10/2021$35.00 → $36.00Buy
    HC Wainwright & Co.
    10/20/2021Outperform
    Cowen
    6/24/2021$35.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $KRON
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CEO Bischofberger Norbert W bought $733,801 worth of shares (615,518 units at $1.19) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      7/1/24 8:27:32 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT & CEO Bischofberger Norbert W bought $3,119,081 worth of shares (3,005,122 units at $1.04) (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      6/12/24 7:23:55 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bischofberger Norbert W bought $1,470,395 worth of shares (1,731,056 units at $0.85), increasing direct ownership by 214% to 2,540,665 units (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      11/17/23 5:41:27 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kronos downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Kronos from Overweight to Neutral and set a new price target of $1.00 from $6.00 previously

      11/14/24 7:43:21 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos downgraded by TD Cowen

      TD Cowen downgraded Kronos from Buy to Hold

      11/14/24 7:42:59 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Kronos with a new price target

      Berenberg initiated coverage of Kronos with a rating of Buy and set a new price target of $12.00

      9/14/22 7:25:57 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Bischofberger Norbert W

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      6/20/25 4:15:37 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Belldegrun Arie

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      6/20/25 4:15:41 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ridloff Elena closing all direct ownership in the company (SEC Form 4)

      4 - Kronos Bio, Inc. (0001741830) (Issuer)

      6/20/25 4:15:35 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Kronos Bio Inc.

      SC 13G/A - Kronos Bio, Inc. (0001741830) (Subject)

      11/14/24 7:58:27 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

      SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)

      7/2/24 9:01:03 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Kronos Bio Inc.

      SC 13D/A - Kronos Bio, Inc. (0001741830) (Subject)

      6/12/24 7:32:56 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right

      CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (NASDAQ:KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that it has entered into a definitive merger agreement (the "Merger Agreement") with Concentra Biosciences, LLC ( "Concentra"), whereby Concentra will acquire Kronos Bio for $0.57 in cash per share of Kronos Bio common stock ("Kronos Bio Common Stock"), plus one non-tradeable contingent value right ("CVR"), which represents the right to receive: (i) 50% of the net proceeds in the case of a disposition of the Company's product ca

      5/1/25 8:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results

      SAN MATEO, Calif., and CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a biopharmaceutical company, today reported fourth quarter and full year 2024 financial results. Fourth Quarter and Full Year 2024 Financial Results Cash, cash equivalents and investments: Cash, cash equivalents and investments as of December 31, 2024, were $112.4 million.R&D Expenses: Research and development expenses were $8.4 million for the fourth quarter of 2024, which includes non-cash stock-based compensation expense of $0.7 million. For the full year of 2024, research and development expenses were $48.7 million, which includes non-cash stock-based compensation expense o

      3/18/25 4:01:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Announces CEO Transition and Reduction in Force

      – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective December 3, 2024. Dr. Knobelman will be the principal executive, financial and accounting officer. She is succeeding Norbert Bischofberger, Ph.D., who will step dow

      11/27/24 7:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    SEC Filings

    See more
    • SEC Form 15-12G filed by Kronos Bio Inc.

      15-12G - Kronos Bio, Inc. (0001741830) (Filer)

      6/30/25 9:00:32 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Kronos Bio Inc.

      EFFECT - Kronos Bio, Inc. (0001741830) (Filer)

      6/24/25 12:15:05 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Kronos Bio Inc.

      S-8 POS - Kronos Bio, Inc. (0001741830) (Filer)

      6/20/25 4:31:16 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Financials

    Live finance-specific insights

    See more
    • Kronos Bio Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study at AACR-NCI-EORTC

      Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed manageable safety profile, with no grade 3/4 neutropenia, dose proportional exposure, dose-dependent target engagement, and 24-hour plasma half-life Dose escalation continues; dosing of patients at the 80 mg dose level is ongoing Enrollment ongoing in dose expansion phase in MYC-dependent and other transcriptionally addicted solid tumors, including lung, ovarian, and triple negative breast cancers Company to host conference call and webcast today at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D.

      10/13/23 12:30:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio To Present Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC and Host Virtual Investor Event on October 13

      SAN MATEO, Calif., and CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will host a conference call and webcast on Friday, October 13, 2023, at 4:30 p.m. ET., followed by a Q&A session. The event will feature trial investigator, Miguel Villalona-Calero, M.D, Medical Oncologist and Director of Early Therapeutics, City of Hope, along with Kronos Bio management, who will discuss the current treatment landscape for patients with MYC-dependent solid tumors, provide an overview of KB-0742 and further discuss the poster to be presented at the AACR-NCI-EORTC Interna

      10/4/23 4:05:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742

      Company to discontinue Phase 3 entospletinib trial for strategic reasons Enrollment continues for Phase 1/2b trial in relapsed/refractory AML with Kronos Bio's next generation SYK inhibitor, lanraplenib Company on track to provide KB-0742 update from ongoing Phase 1/2 clinical trial in Q4 With $270.3 million in cash, cash equivalents and investments as of Sept. 30, 2022, Kronos Bio extends expected cash runway from Q4 2024 into Q2 2025 Conference call and webcast scheduled for today at 4:30 p.m. ET SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to transforming the lives of those affected by cancer, today

      11/8/22 4:05:00 PM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $KRON
    Leadership Updates

    Live Leadership Updates

    See more
    • Kronos Bio Announces CEO Transition and Reduction in Force

      – Norbert Bischofberger, Ph.D., is stepping down from his role as President & CEO – – Deborah Knobelman, Ph.D., COO & CFO, is named President & Interim CEO – SAN MATEO, Calif. and CAMBRIDGE, Mass., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company developing small molecule therapeutics to address cancers and other diseases driven by deregulated transcription, today announced that its Board of Directors has appointed Deborah Knobelman, Ph.D., as President and Interim Chief Executive Officer, effective December 3, 2024. Dr. Knobelman will be the principal executive, financial and accounting officer. She is succeeding Norbert Bischofberger, Ph.D., who will step dow

      11/27/24 7:30:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer

      SAN MATEO, Calif. and CAMBRIDGE, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it has appointed Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer effective June 3, 2024. Dr. Knobelman will oversee the finance, accounting, business development, investor relations and corporate strategy functions. "I'm excited to have Deb join our team. She is a proven life sciences leader, and her strategic vision will play a critical role in shaping the future of Kronos Bio. As we continue to

      5/21/24 8:15:00 AM ET
      $KRON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments